作者: Jason C Hsu , Luis A Gonzalez-Gonzalez , Vicky H Lu , Christine Y Lu
DOI: 10.1136/BMJOPEN-2015-010706
关键词: Evidence-based practice 、 Market share 、 Eye neoplasm 、 Intensive care medicine 、 Retrospective cohort study 、 Medicine 、 Health economics 、 Medical prescription 、 Epidemiology 、 Health policy
摘要: Objectives This study examined the recent trend in use and costs of antineoplastic agents for treatment eye malignancies Taiwan from 2009 to 2012. We also forecasted targeted therapies up including year 2016 based on current patterns. Design Retrospective observational focusing usage malignancy. Setting The monthly claims data malignancy-related were retrieved Taiwan's National Health Insurance Research Database (2009–2012). Main outcome measures calculated number prescriptions each class medications, analysed their time trends. In addition, using a series design with ARIMA models, we estimated market share by prescription volume proportion 2016. Results grew 1.56% 9.98% 2012 among all agents, rose 15.12% 58.88% Especially, protein kinase inhibitors 25.62% 45.28% between 2010 predicted reach 27.33% 91.39% fourth quarter 2016, respectively. Conclusions is first that Taiwan. Our findings indicate that, compared other classes drugs, are having more relevant strategies Taiwan, due high they likely cause great economic burden.